Fig. 1: The bioinformatic analysis supports Gαi3 overexpression in pancreatic cancer.
From: Identification of Gαi3 as a promising molecular oncotarget of pancreatic cancer
The Cancer Genome Atlas (TCGA) PAAD database shows the mRNA levels of Gαi3 (GNAI3) in pancreatic cancer tissues (“Tumor”, n = 171) and normal pancreatic tissues (“Normal”, n = 179) (A), and the Kaplan–Meier Survival analyses of overall survival (B), disease-specific survival (C), and progression-free survival (D) were performed based on Gαi3 expression in TCGA-PAAD dataset. The receiver operating characteristic(ROC) curves for evaluating the prognostic potential of Gαi3 overexpression in relation to the overall survival probability of pancreatic cancer patients were shown (E–H). Subgroup analyses explore the correlation between Gαi3 expression levels and distinct clinical characteristics of pancreatic cancer patients (I–L). “TPM” refers to transcripts per million, “AUC” denotes the area under the curve, “HR” represents the hazard rate, “TPR” is the true positive rate, and “FPR” stands for the false positive rate. *P < 0.05. “N.S.” stands for non-statistical difference (P > 0.05).
